CD44-Targeting Nanoparticles for Cancer Stem Cell Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies fail to effectively target and eliminate cancer stem cells, which are resistant to chemotherapy and radiation and contribute to cancer recurrence, due to challenges in systemically delivering siRNAs to primary tumors and metastases.
Innovation Solution
Development of nanoparticles comprising cationic molecules like DLPE and DLPG that condense polynucleotides through electrostatic interactions, covalently bound to a targeting moiety such as Hyaluronic Acid at a pH below 4.5, creating homogeneous particles capable of selectively delivering siRNAs or miRNAs to CD44-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If siRNAs are systemically delivered to target cancer stem cells, then gene silencing efficacy is improved, but delivery specificity and stability in circulation are worsened
Solution Approach 1:
The patent uses composite nanoparticles composed of cationic molecules (for siRNA condensation), hyaluronic acid (for CD44 targeting), and PEG (for stealth properties and serum resistance). This composite structure enables simultaneous achievement of stable circulation, specific targeting, and effective gene silencing, resolving the contradiction between delivery efficacy and specificity
Solution Approach 2:
The nanoparticle surface is functionalized with hyaluronic acid at specific locations to bind CD44 receptors on cancer stem cells, while the core maintains siRNA condensation properties. This localized functional differentiation allows the particle to exhibit both systemic stability and target-specific delivery
2Productivity
If nanoparticles are designed to target CD44-expressing cells, then cancer stem cell elimination is improved, but off-target effects on normal cells are worsened
Solution Approach 1:
The patent exploits the differential expression parameter of CD44 receptor between cancer stem cells (high expression) and normal cells (low or moderate expression). By designing nanoparticles that specifically bind to CD44, the system achieves selective accumulation in cancer stem cells while minimizing off-target effects on normal tissues
Solution Approach 2:
Hyaluronic acid serves as an intermediary targeting ligand that mediates specific recognition between the nanoparticle and CD44 receptors on cancer stem cells. This intermediary enables selective delivery to the intended target while sparing normal cells that do not overexpress the receptor
3Adaptability or versatility
If siRNAs are delivered systemically, then treatment of occult metastases is improved, but serum degradation of siRNAs is worsened
Solution Approach 1:
The nanoparticle employs a PEGylated shell that provides steric protection to the encapsulated siRNA, preventing serum nucleases from degrading the siRNA during circulation. This protective shell enables systemic delivery to both primary tumors and occult metastases while maintaining siRNA integrity
Solution Approach 2:
The siRNA is nested within the nanoparticle core, surrounded by cationic molecules that condense the siRNA and protect it from degradation. This nested structure allows the siRNA to circulate systemically without exposure to degrading enzymes in the serum
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles achieve potent gene silencing and eradication of cancer stem cells with high specificity and efficiency, avoiding interferon responses and serum degradation, making them suitable for in vivo therapy.
Implementation Method 1
contacting the polynucleotide with a composition comprising a cationic 1,2-Dilauroyl-sn-Glicero-3-Phosphoethanolamine (DLPE) and 1,2-Dilauroyl-sn-Glicero-3-Glycerol (DLPG), wherein said DLPE and DLPG condense the polynucleotide by electrostatic interactions to generate a complex
Implementation Method 2
covalently binding said complex to a targeting moiety at a pH equal to or below 4.5 (± 5%), thereby generating the particle for delivery of the polynucleotide to the target cell, wherein the targeting moiety comprises Hyaluronic Acid (HA)
Data Source
Figure 1A~1B
Figure 2A~2F
Figure 3
AI summary
A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome; and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed.